BCL2L1 - BCL2 like 1 Gene
Species: Oryctolagus cuniculus
Gene Type: protein coding
Gene ID: 100008875
About BCL2L1
Chromosome 4: 7,512,085-7,567,980 forward strand.OryCun2.0:CM000793.1
This gene has 1 transcript (splice variant), 285 orthologues and 7 paralogues.
BCL2L1 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001082135.1 | NP_001075604.1 | bcl-2-like protein 1 |
BCL2L1 Protein Structure
bcl-2
bcl-2: TIGR00865 (0 - 232)
- 0
- 100
- 200
- 233 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
bcl-2-like protein 1 |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B0420A | Moroxydine hydrochloride | Inhibitor | 99.36% | Unkown |
Clinical Phase
Bioactive Molecules
(5)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-N1423 | Glycocholic acid | 99.90% | Phase 3 | |
| HY-10969 | Obatoclax Mesylate | 99.85% | Phase 3 | |
| HY-10969A | Obatoclax | ≥99.0% | Phase 3 | |
| HY-15464 | (R)-(-)-Gossypol | 99.37% | Phase 2 | |
| HY-15464A | (R)-(-)-Gossypol acetic acid | 98.93% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(44)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-N1423A | Glycocholic acid sodium | 97.0% | Unkown | |
| HY-N1423S | Glycocholic acid-d4 | 99.92% | Unkown | |
| HY-125876 | PROTAC Bcl2 degrader-1 | Inhibitor | 99.80% | Unkown |
| HY-153803 | GBD-9 | Degrader | 99.91% | Unkown |
| HY-W013105 | Sodium glycocholate hydrate, 98% | 99.91% | Unkown | |
| HY-132307 | Mcl-1 inhibitor 6 | 98.77% | Unkown | |
| HY-N1423B | Glycocholic acid hydrate | 99.85% | Unkown | |
| HY-135273 | A-1211212 | 98.43% | Unkown | |
| HY-19551 | Apogossypolone | 98.58% | Unkown | |
| HY-N1423S1 | Glycocholic acid-d5 | 99.9% | Unkown | |
| HY-15191B | (S)-Sabutoclax | Inhibitor | 98.03% | Unkown |
| HY-RS01421 | BCL2L1 Human Pre-designed siRNA Set A | / | Unkown | |
| HY-114310 | VDR agonist 1 | / | Unkown | |
| HY-123715 | Anticancer agent 255 | / | Unkown | |
| HY-144428 | Bcl-2/Mcl-1-IN-2 | Inhibitor | / | Unkown |
| HY-144430 | Bcl-2/Mcl-1-IN-1 | Inhibitor | / | Unkown |
| HY-144431 | Bcl-2/Mcl-1-IN-3 | Inhibitor | / | Unkown |
| HY-147826 | EGFR-IN-60 | / | Unkown | |
| HY-149436 | CDK2/Bcl2-IN-1 | Inhibitor | / | Unkown |
| HY-149681 | Beclin1-Bcl-2 interaction inhibitor 1 | Inhibitor | / | Unkown |
| HY-159513 | Bcl-2/Mcl-1-IN-4 | Inhibitor | / | Unkown |
| HY-161415 | BCL-xL/BCL-2 ligand 1 | / | Unkown | |
| HY-169083 | Bcl-2-IN-22 | Inhibitor | / | Unkown |
| HY-174338 | GPER/Bcl-2-IN-1 | Inhibitor | / | Unkown |
| HY-174403 | c-MYC/BCL2 ligand 1 iodide | / | Unkown | |
| HY-174404 | Topoisomerase II inhibitor 23 | / | Unkown | |
| HY-178910 | Mcl-1-IN-20 | / | Unkown | |
| HY-180371 | NF-115 | Inducer | / | Unkown |
| HY-181746 | Bcl-2/Mcl-1-IN-5 | / | Unkown | |
| HY-183369 | VEGFR/PD-L1-IN-1 | / | Unkown | |
| HY-N20627 | Withametelin B | / | Unkown | |
| HY-N3828 | epi-Eriocalyxin A | / | Unkown | |
| HY-RS01418 | BCL2A1 Human Pre-designed siRNA Set A | / | Unkown | |
| HY-RS01419 | Bcl2a1 Rat Pre-designed siRNA Set A | / | Unkown | |
| HY-RS01420 | Bcl2a1a Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS01422 | Bcl2l1 Mouse Pre-designed siRNA Set A | / | Unkown | |
| HY-RS01423 | Bcl2l1 Rat Pre-designed siRNA Set A | / | Unkown | |
| HY-W016937 | Moroxydine | Inhibitor | / | Unkown |
| HY-W713297 | Moroxydine hydrochloride-d8 | Inhibitor | / | Unkown |
| HY-W754548 | Glycocholic acid-13C2,d4 | / | Unkown | |
| HY-12011A | (Rac)-HA14-1 | Inhibitor | / | Unkown |
| HY-174635 | Human IL15RA mRNA | / | Unkown | |
| HY-N6926 | 1,3,5-Tricaffeoylquinic acid | / | Unkown | |
| HY-N8579 | Eugenyl benzoate | ≥90.0% | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service